TY - JOUR
T1 - Clinical characteristics of patients with resistant hypertension
T2 - the RESIST-POL study
AU - Florczak, E.
AU - Prejbisz, A.
AU - Szwench-Pietrasz, E.
AU - Śliwiński, P.
AU - Bieleń, P.
AU - Klisiewicz, A.
AU - Michałowska, I.
AU - Warchoł, E.
AU - Januszewicz, M.
AU - Kała, M.
AU - Witkowski, A.
AU - Wiȩcek, A.
AU - Narkiewicz, K.
AU - Somers, V. K.
AU - Januszewicz, A.
N1 - Funding Information:
The study was supported by the Ministry of Science and Higher Education NN 402 190 335.
Funding Information:
EF, AP, ES, AK, IM, EW, AW, and AJ have worked at the center receiving per-patient payment for studies involvement from Ardian-Medtronic. EF, AP, AdW, AnW, KN and AJ have received research grants from the Ministry of Science and Higher Education. VKS has served as a consultant for Johnson and Johnson, Medtronic, ResMed, Respironics, Apnex Medical, Neu Pro, Deshum and Sova Pharmaceuticals. He has received research grants from the Respironics Foundation and National Institutes of Health.
PY - 2013/11
Y1 - 2013/11
N2 - Recent studies indicate that resistant hypertension (RHTN) is present in about 12% of the treated hypertensive population. However, patients with true RHTN (confirmed out of the office) have not been widely studied. We prospectively studied 204 patients (123 male, 81female, mean age 48.4 years, range 19-65 years) with truly RHTN (ambulatory daytime mean blood pressure >135/85 mm Hg). We evaluated the frequency of obstructive sleep apnea (OSA), renal artery stenosis (RAS), primary aldosteronism (PA) and other secondary forms of hypertension (HTN) and conditions. Mild, moderate and severe OSA were present in 55 (27.0%), 38 (18.6%) and 54 (26.5%) patients, respectively. Secondary forms of HTN were diagnosed in 49 patients (24.0%), the most frequent being PA (15.7%) and RAS (5.4%). Metabolic syndrome (MS) was present in 65.7% of patients. Excessive sodium excretion was evident in 33.3% of patients and depression in 36.8% patients. In patients with RHTN, OSA and MS were the most frequent conditions, frequently overlapping with each other and also with PA. Our data indicate that in the vast majority of patients with truly RHTN, at least one of three co-morbidities - OSA, MS and PA - is present. Other conditions, even though less frequent, should also be taken into the consideration.
AB - Recent studies indicate that resistant hypertension (RHTN) is present in about 12% of the treated hypertensive population. However, patients with true RHTN (confirmed out of the office) have not been widely studied. We prospectively studied 204 patients (123 male, 81female, mean age 48.4 years, range 19-65 years) with truly RHTN (ambulatory daytime mean blood pressure >135/85 mm Hg). We evaluated the frequency of obstructive sleep apnea (OSA), renal artery stenosis (RAS), primary aldosteronism (PA) and other secondary forms of hypertension (HTN) and conditions. Mild, moderate and severe OSA were present in 55 (27.0%), 38 (18.6%) and 54 (26.5%) patients, respectively. Secondary forms of HTN were diagnosed in 49 patients (24.0%), the most frequent being PA (15.7%) and RAS (5.4%). Metabolic syndrome (MS) was present in 65.7% of patients. Excessive sodium excretion was evident in 33.3% of patients and depression in 36.8% patients. In patients with RHTN, OSA and MS were the most frequent conditions, frequently overlapping with each other and also with PA. Our data indicate that in the vast majority of patients with truly RHTN, at least one of three co-morbidities - OSA, MS and PA - is present. Other conditions, even though less frequent, should also be taken into the consideration.
KW - metabolic syndrome
KW - obstructive sleep apnea
KW - primary aldosteronism
KW - renal artery stenosis
KW - resistant hypertension
UR - http://www.scopus.com/inward/record.url?scp=84885589246&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84885589246&partnerID=8YFLogxK
U2 - 10.1038/jhh.2013.32
DO - 10.1038/jhh.2013.32
M3 - Article
C2 - 23698004
AN - SCOPUS:84885589246
SN - 0950-9240
VL - 27
SP - 678
EP - 685
JO - Journal of Human Hypertension
JF - Journal of Human Hypertension
IS - 11
ER -